SavedAdd your journal

Journals / Turkish Journal of Veterinary and Animal Sciences / 2005 / Cilt: 29 - Sayı: 2

In Vitro Efficacy of Azithromycin and Roxithromycin Against Toxoplasma gondii

Mehmet TANYÜKSEL
Pages
525–529
Publication Date
2005-02-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was found that azithromycin and roxithromycin had significant microbicidal activity (P < 0.05).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Toxoplasmosis is a common problem, accounting for significant morbidity in developing countries.
📊
Key Findings & Data:Better-tolerated and more effective drugs are clearly needed.
💡
Conclusion & Impact:It was found that azithromycin and roxithromycin had significant microbicidal activity (P < 0.05).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Toxoplasma gondii · azithromycin · roxithromycin

Abstract

Toxoplasmosis is a common problem, accounting for significant morbidity in developing countries. Conventional treatments are associated with frequent relapses and with additional problems including undesirable side effects. Better-tolerated and more effective drugs are clearly needed. The aim of this study is to evaluate the in vitro efficacy of azithromycin and roxithromycin against Toxoplasma gondii using acridine orange in the fluorescence microscopic assay. It was found that azithromycin and roxithromycin had significant microbicidal activity (P < 0.05). In conclusion, this observation should be assessed carefully in future clinical trials involving a large number of cases with toxoplasmosis.

Özet

Toxoplasmosis is a common problem, accounting for significant morbidity in developing countries. Conventional treatments are associated with frequent relapses and with additional problems including undesirable side effects. Better-tolerated and more effective drugs are clearly needed. The aim of this study is to evaluate the in vitro efficacy of azithromycin and roxithromycin against Toxoplasma gondii using acridine orange in the fluorescence microscopic assay. It was found that azithromycin and roxithromycin had significant microbicidal activity (P < 0.05). In conclusion, this observation should be assessed carefully in future clinical trials involving a large number of cases with toxoplasmosis.

🔖

Cite This Article

TANYÜKSEL, M. (2005). In Vitro Efficacy of Azithromycin and Roxithromycin Against Toxoplasma gondii. Turkish Journal of Veterinary and Animal Sciences, Cilt: 29 - Sayı: 2, 525–529. https://ajindex.com/articles/122375

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Georgiev, V.S.: Management of toxoplasmosis. Drugs 1994; 48:179-188. 2. Vannuffel, P., Cocito, C.: Mechanism of action of streptogramins and macrolids. Drugs, 1996; 51 (Suppl. 1): 20-30. 3. Khan, A.A., Slifer, T.R., Araujo, F.G., Remington, J.S.: Quinupristin-Dalfopristin is active against Toxoplasma gondii. Hoepelman, I.M., Scheneider, M.M.E.: Azithromycin: the first of the tissue-selective azalides. Int. J. Antimicrob. Agents, 1995; 5: 145-167.
  2. Jaruratanasirikul, S., Hortiwakul, R., Tantisarasart, T., Phuenpathom, N., Tussanasunthornwong, S.: Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob. Agents Chemother., 1996; 40: 825-826.
  3. Fichera, M.E., Mahendra, K.B., Roos, D.S.: In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob. Agents Chemother., 1995; 39: 1530-1537.
  4. Rothova, A., Bosch-Driessen, L.E., van Loon, N.H., Treffers, W.F.: Azithromycin for ocular toxoplasmosis. Br. J. Ophthalmol., 1998; 82: 1306-1308.
  5. Brun-Pascaud, M., Rajagopalan-Levasseur, P., Chau, F., Bertrand, G., Garry, L., Derouin, F., Girard, P.M.: Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model. Antimicrob. Agents Chemother., 1998; 42: 1068-1072.
  6. Romand, S., Bryskier, A., Moutot, M., Derouin, F.: In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii. J. Antimicrob. Chemother., 1995; 35: 821-832.
  7. Beckers, C.J.M., Roos, D.S., Donald, R.G.K., Luft, B.J., Schwab, J.C., Cao,Y., Joiner, K.A.: Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics. J. Clin. Invest., 1995; 95: 367- 376. Tripodi, M.F., Adinolfi, L.E., Utili, R., Marrone, A., Ruggiero, G.: Influence of subinhibitory concentrations of Loracarbef (LY 163892) and Laptomycin (LY 146032) on bacterial phagocytosis, killing and serum sensitivity. J. Antimicrobiol. Chem., 1990; 26: 491-501.
  8. Derouin, F.: New pathogens and mode of action of azithromycin: Toxoplasma gondii. Pathol. Biol. Paris, 1995; 43: 561-564.